Humacyte Q4 2024 Earnings Preview
Source: SeekingAlpha
2025-03-27 12:55:20 ET
More on Humacyte
- Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel
- Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
- Humacyte: Upside Potential, But I Will Wait For Revenue Trends
- Biggest stock movers Wednesday: GME, HUMA, DLTR, and more
- Humacyte stock slides on pricing public offering of units to raise $50M
Read the full article on Seeking Alpha
For further details see:
Humacyte Q4 2024 Earnings Preview
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
-15.13% G/L:
$0.7011 Last:
9,692,111 Volume:
$0.7406 Open:
HUMA Latest News
March 27, 2026 07:00:00 am
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 26, 2026 08:00:00 am
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
